Frank A. Holler - May 27, 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Stock symbol
XENE
Transactions as of
May 27, 2021
Transactions value $
-$180,880
Form type
4
Date filed
6/1/2021, 04:07 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $11.6K +3.09K +2.53% $3.76* 125K May 27, 2021 Direct F1
transaction XENE Common Shares Tax liability -$9.57K -507 -0.41% $18.88 125K May 27, 2021 Direct F2
transaction XENE Common Shares Options Exercise $135K +36K +28.89% $3.76* 161K May 27, 2021 Direct F1
transaction XENE Common Shares Tax liability -$112K -5.91K -3.68% $18.88 155K May 27, 2021 Direct F2
transaction XENE Common Shares Sale -$48.2K -2.58K -1.67% $18.69 152K May 27, 2021 Direct F3
transaction XENE Common Shares Sale -$158K -8.49K -5.58% $18.68 144K May 27, 2021 Direct F4
holding XENE Common Shares 1.18K May 27, 2021 Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -3.09K -100% $0.00* 0 May 27, 2021 Common Shares 3.09K $3.76 Direct F1, F5, F6
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -36K -100% $0.00* 0 May 27, 2021 Common Shares 36K $3.76 Direct F1, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F2 Represents the closing price of the Company's common shares on May 26, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
F3 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.51 to $18.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein
F4 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.54 to $18.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein
F5 The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.
F6 Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period.